Atlas Trials

A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

Clinical trial NCT07701993 · RECRUITING

Trial details

NCT number
NCT07701993
Sponsor
GlaxoSmithKline
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Metabolic Dysfunction-associated Steatohepatitis
Start date
2026-07-22
Primary completion
2033-07-27
Enrollment
1740

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.